Counseling
Learn more about how oncology social workers can help you cope with a cancer diagnosis.
Resource Navigation
Learn more about how CancerCare Resource Navigation can help you address barriers to care.
Connect Education Workshops
Listen in by telephone or online as leading experts in oncology provide up-to-date information about cancer-related issues in one-hour workshops. Podcasts are also available.
Upcoming
For Acute Lymphoblastic Leukemia
For Acute Myeloid Leukemia
For Chronic Lymphocytic Leukemia
For Chronic Myelogenous Leukemia
For Cutaneous T-Cell Lymphoma
For Diffuse Large B-Cell Lymphoma
For Follicular Lymphoma
For Hodgkin Lymphoma
For Leukemia
For Lymphoma
For Mantle Cell Lymphoma
For Marginal Zone Lymphoma
For Multiple Myeloma
For Myelodysplastic Syndromes
For Myelofibrosis
For Myeloproliferative Neoplasms
For Non-Hodgkin Lymphoma
For Peripheral T-Cell Lymphoma
For Polycythemia Vera
For Small Lymphocytic Lymphoma
For Waldenstrom’s Macroglobulinemia
Podcasts
Clinical Trials
- Metastatic Triple Negative Breast Cancer: Strategies to Cope, Oct 23, 2024
- Triple Negative Breast Cancer and African American Women, Oct 16, 2024
- Highlights from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting: The Art and Science of Cancer Care from Comfort to Cure, Sep 24, 2024
- Updates from the American Society of Clinical Oncology (ASCO) 2024 on Triple Negative Breast Cancer, Sep 11, 2024
- Diverse Populations Living with Multiple Myeloma: Treatment Advances, Mar 28, 2024
- Bladder Cancer: Treatment Updates, Jan 24, 2024
- Updates in the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive and HER2 Positive Breast Cancer from the 46th Annual San Antonio Breast Cancer Symposium (SABCS), Jan 17, 2024
- The Benefits of Clinical Trials for Triple Negative Breast Cancer, Jan 10, 2024
- Updates from the 2023 American Society of Hematology (ASH) Annual Meeting, Dec 14, 2023
- Living with Breast Cancer - 46th Annual San Antonio Breast Cancer Symposium, Dec 13, 2023
- Metastatic Prostate Cancer: Current Treatment Advances, Oct 31, 2023
- Metastatic Breast Cancer: Treatment Updates, Oct 11, 2023
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”, Aug 22, 2023
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”, Aug 17, 2023
- Liver Cancer: Treatment Update, Jun 12, 2023
- Clinical Trials: How They Transform the Treatment of Cancer, Jun 7, 2023
- Oral, Head and Neck Cancer: Treatment Updates, May 31, 2023
- Update on Small Cell Lung Cancer, May 30, 2023
- Mesothelioma: Innovative Treatment Options, May 1, 2023
- Progress in the Treatment of Multiple Myeloma, Apr 13, 2023
- Managing the Side Effects of Immunotherapy, Apr 5, 2023
- Understanding the Role of Immunotherapy in Treating Cancer, Mar 22, 2023
- Non-Small Cell Lung Cancer: Biomarker Testing & Treatment Trends, Mar 21, 2023
- Bladder Cancer: Treatment Updates, Mar 8, 2023
- Liver Cancer: Treatment Updates, Feb 6, 2023
- Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer, Dec 20, 2022
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting, Dec 15, 2022
- Advances in the Treatment of Colorectal Cancer, Dec 5, 2022
- The Benefits of Clinical Trials for Triple Negative Breast Cancer, Nov 2, 2022
- Metastatic Triple Negative Breast Cancer, Oct 26, 2022
- Metastatic Breast Cancer: Treatment Updates, Oct 12, 2022
- Bladder Cancer: Treatment Update, Aug 17, 2022
- Progress in the Treatment of Multiple Myeloma, Jul 28, 2022
- HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life, Jun 29, 2022
- What’s New in Diagnostic Technologies for People Living with Small Cell Lung Cancer, Jun 28, 2022
- Genomic Testing and Current Trends in the Treatment of Non-Small Cell Lung Cancer, Jun 21, 2022
- Mesothelioma: Innovative Treatment Options, Jun 13, 2022
- The Role of Radiation Therapy in the Treatment of Breast Cancer, Jun 8, 2022
- Oral, Head & Neck Cancer: Treatment Update, Jun 1, 2022
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress, May 25, 2022
- Clinical Trials: How They Transform the Treatment of Cancer, May 18, 2022
- Colorectal Cancer Treatment: Progress and Advances, May 16, 2022
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches, Apr 28, 2022
- Managing the Side Effects of Immunotherapy, Apr 27, 2022
- Trends in Oncology and Treatment Planning: What You Need to Know, Mar 4, 2020
Publications
Read or order our free Connect booklets and fact sheets offering easy-to-read information about the latest cancer treatments, managing side effects and coping with cancer.
For Any Cancer Diagnosis
- Clinical Trials: Improving the Care of People Living With Cancer
- Clinical Trials: What You Need to Know
- The Role of Clinical Trials in Your Cancer Treatment
For Glioblastoma
For Brain Cancer
For Lung Cancer
For Esophageal Cancer
For Myeloproliferative Neoplasms
Financial Assistance
Limited assistance from CancerCare is available to help with cancer-related costs.
Ask CancerCare
Every month, featured experts answer your questions about coping with cancer including specific answers to questions asked by caregivers.
For Any Cancer Diagnosis
- Q.
What is "compassionate use"?
A.Being part of a clinical trial is the most common way that patients receive investigational drugs (i.e. drugs that have not yet been “FDA-approved”). The term “compassionate use” or “compassionate exemption” means that a patient is allowed to receive a drug even though he/she does not meet the eligibility criteria of a clinical trial in which a drug is being studied.
The decision to provide a drug in this manner is made on a case-by-case basis and there must be a reasonable expectation the drug will prolong life or improve a person’s quality of life. In addition, the sponsor of the clinical trial must agree to make the drug available and, as noted in a National Cancer Institute fact sheet, Access to Investigational Drugs, the drug being studied must also meet the following criteria:
- There must be substantial clinical evidence that the drug may benefit persons with particular type of cancer.
- The drug must be able to be given safely outside a clinical trial.
- The drug must be in sufficient supply for ongoing and planned clinical trials.
Should you have any further questions, there are three ways you can contact the National Cancer Institute’s Cancer Information Service (CIS):
- By telephone: U.S. residents may call the CIS toll-free at 800-4-CANCER (1-800-422-6237).
- Over the Internet: You may use instant messaging through LiveHelp.
- By email: You can send e-mail using an online contact form.
- Q.
Are there any new clinical trials available for someone with advanced cancer that's spread to his bones?
A.The first step in locating appropriate trials is to contact his oncologist. The oncologist is most familiar with your loved one’s case and can inform him of clinical trials for his type and stage of cancer. They can also advise him about whether he qualifies for a study and help him contact the researchers involved.
You can also find listings of specific clinical trials to discuss with the oncologist:
- National Cancer Institute’s Cancer Information Service sponsors most government-funded cancer clinical trials. The NCI has a list of active studies, as well as some privately funded studies. You can contact them at 1-800-4-CANCER or conduct a search on their website.
- ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine. They have a large list of trials, though not all are cancer-related. Like the National Cancer Institute, you can conduct an online search to find trials that best fit with your loved one’s situation.
To learn more about clinical trials please visit CancerCare’s Clinical Trials webpage.
For Lung Cancer
- Q.
My husband has just been diagnosed with small cell lung cancer with small tumors in his liver. He starts chemo next week with 4 hours, day 1 and 2 hours, day 2 and 3. He repeats this every 18 days for six sessions. Is this the normal treatment for small cell lung cancer? Where would I look to find information on clinical trials?
A.Later-stage small cell lung cancer is characterized by a spread of the disease from the lungs to other organs such as the liver, and is normally treated with aggressive chemotherapy. Since the treatment is aggressive, it must be administered over a number of days for each session, and the sessions are spaced out with non treatment breaks of 18 to 21 days to make sure that the patient’s overall health is not affected. Patients whose tumors respond well to chemotherapy may be considered for a radiation treatment to the brain called Prophylactic Cranial Irradiation (PCI) in which the entire brain receives radiation with the intent of stopping the spread of the disease. For more information about the treatment of small cell lung cancer, please visit the National Cancer Institute’s website.
CancerCare collaborates with EmergingMed’s clinical trials matching service, which is designed to assist lung cancer patients in identifying and accessing clinical trials which may be appropriate to their medical situation.
- Q.
How does one get compassionate care in clinical trials when there is nothing left in the way of lung cancer treatments?
A.We believe you are asking about “Compassionate Drug Use” also called “Compassionate Use,” which is the use of therapeutic drugs that have not yet been approved by the FDA to treat cancer, and no other treatments are available. These drugs are called investigational drugs and are usually only available to patients who are participating in a clinical trial. Use of these drugs outside of a clinical trials is extremely limited.
Requests for the compassionate use of an investigational drug must be made via a request from the patient’s doctor to the drug company requesting their permission for its use and their willingness to supply the drug for the patient’s use. If the drug company consents, and frequently they do not, then the doctor must ask the FDA for their permission to use the drug for his or her patient only. The request to the FDA must include detailed medical information about the patient, why the request is necessary, a proposed plan of treatment and the patient’s signed consent. The length of time for FDA approval varies, but may be expedited in emergency situations.
For more information on compassionate drug use, the American Cancer Society provides a helpful reference guide.
For Breast Cancer
- Q.
My mother has stage 4 breast cancer and I'd like to know if she would be eligible for any clinical trials.
A.Whether or not a clinical trial would be an option for your mother will be determined by several factors. The guidelines that clinical trials follow state who will be able to join the study, based on the questions the research is trying to answer. Therefore, your mother’s type of cancer, as well as the stage of her disease, her age and whether she has received any prior treatment would be examples of some of the eligibility criteria that may come into play. I would encourage you and your mother to speak to her doctor about this important question, since only her doctor can determine whether a clinical trial would be appropriate.
To locate clinical trials that might be suitable for her, call the National Cancer Institute’s (NCI) Cancer Information Service at 1-800-422-6237, or you can search the NCI’s clinical trials database. If you need help using our clinical trials online search form, read Help Using the NCI Clinical Trials Search Form.
CancerCare’s clinical trials publications are also excellent resources.
For Metastatic Breast Cancer
- Q.
My mother has stage 4 breast cancer and I'd like to know if she would be eligible for any clinical trials.
A.Whether or not a clinical trial would be an option for your mother will be determined by several factors. The guidelines that clinical trials follow state who will be able to join the study, based on the questions the research is trying to answer. Therefore, your mother’s type of cancer, as well as the stage of her disease, her age and whether she has received any prior treatment would be examples of some of the eligibility criteria that may come into play. I would encourage you and your mother to speak to her doctor about this important question, since only her doctor can determine whether a clinical trial would be appropriate.
To locate clinical trials that might be suitable for her, call the National Cancer Institute’s (NCI) Cancer Information Service at 1-800-422-6237, or you can search the NCI’s clinical trials database. If you need help using our clinical trials online search form, read Help Using the NCI Clinical Trials Search Form.
CancerCare’s clinical trials publications are also excellent resources.
Specialized Programs
CancerCare offers specialized programs to address specific populations and concerns.
Community Programs
Learn about and view the full calendar of our free community programs.
Coping Circle Workshops
Virtual educational and supportive workshops led by oncology social workers and qualified co-facilitators. These workshops cover numerous topics and are offered in English and Spanish.
Additional Resources
Organizations
BreastCancerTrials.org
ClinicalTrials.gov
EmergingMed
Lazarex Cancer Foundation
myTRIAList.org